Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ONE2ZEE
Rotterdam, South Holland, Netherlandsone2zee.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
One2Zee is a Dutch biotechnology company focused on developing transformative therapies for rare neurodevelopmental disorders, with a primary focus on Angelman syndrome. The company's approach centers on identifying and modulating specific protein-protein interactions that are critical to neuronal function and development. By leveraging deep expertise in the molecular mechanisms of the brain, One2Zee aims to restore normal cellular processes in patients with severe genetic conditions. Their lead programs are currently in the pre-clinical stage, targeting the underlying causes of synaptic dysfunction.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Erasmus University Medical Center
Beyond the preview
Go deeper on ONE2ZEE.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ONE2ZEE.